Currently recruiting for the following tumor types:

**DOGS** - Osteosarcoma, histiocytic sarcoma, mast cell tumors, transitional cell carcinoma (bladder)

**CATS** – No enrolling trials at this time.

1. **TUMOR TYPE: APPENDICULAR OSTEOSARCOMA** – new study
   **TRIAL:** Standard of care vs. standard of care plus an investigational agent for the treatment of appendicular osteosarcoma.

   This is a randomized clinical trial for dogs with newly diagnosed appendicular osteosarcoma sponsored by Morris Animal foundation and the National Cancer Institute. All dogs will receive standard of care therapy as a part of the trial. Once the standard of care treatment is completed, some dogs may receive an investigational agent. A screening visit to determine eligibility is required. The trial is **FUNDED.** *PI- Dr. Olya Smrkovski, opuretsk@utk.edu.*

2. **TUMOR TYPE: Canine mast cell tumor**
   **TRIAL:** Use of Kinavet (masitinib) for non-resectable canine mast cell tumors.

   This is a double-blinded placebo-control trial that evaluates Kinavet in dogs with non-resectable mast cell tumors (2/3 of the dogs will receive Kinavet, 1/3 – placebo). Dogs cannot be on chemotherapy and should be off steroids for at least 3 weeks. Must have gross disease. A screening visit to determine eligibility is required. The trial is **FULLY FUNDED,** including screening visit. *PI- Dr. Olya Smrkovski, opuretsk@utk.edu.*

3. **TUMOR TYPE: Canine Bladder transitional cell carcinoma**
   **TRIAL:** Evaluating a novel optical imaging agent, fluorocoxib A, to detect cyclooxygenase-2 (COX-2) expressing cancers of bladder in female dogs.

   COX-2 enzyme is highly present in cancer cells, but not in normal cells that makes an attractive target for detection of cancer. This study using fluorocoxib A in dogs with naturally occurring cancers will assist to identify tumors that would benefit from COX-2 targeted NSAIDs. In addition, this study will assist to translate this novel imaging agent into clinical applications for detection of cancer, as well for monitoring the early responses to therapy not only in dogs, but also in human patients. This trial includes financial incentives to the client. Patients may be enrolled undiagnosed and the trial will pay for biopsy for diagnosis. Patients must be off NSAIDs for 2 weeks before enrollment or biopsy. Female dogs only. Trial period is approximately 24 hours. *PI- Dr. Maria Cekanova, mcekanov@utk.edu*

4. **TUMOR TYPE: HISTIOCYTIC SARCOMA**
   **TRIAL:** Phase II, Open Label Trial of Paccal Vet® (water-soluble micellar paclitaxel) in Dogs with Histiocytic Sarcoma.

   The trial will evaluate a new canine chemotherapy agent, Paccal Vet, for canine histiocytic sarcoma. Paccal Vet has been studied in other canine tumors. This trial includes financial incentives to the client (Paccal vet provided at no cost, additional staging tests are covered to determine response). Trial period is a minimum of 6 weeks (3 required visits to UT), but additional Paccal Vet provided if dog responds to treatment. Patients need to be off other therapies (including steroids) for 2 weeks prior to enrollment. *PI- Dr. Jeanne Larson jlarson8@utk.edu.*

5. **Coming Soon: Nutrition in Canine Lymphoma**
   *PI contact information is provided for referring veterinarians only.*
PLEASE NOTE:

For all trials, patients must be examined at UTCVM to determine eligibility. **If a patient is being seen specifically for clinical trial evaluation, please contact the Clinical Trials Coordinator to schedule an appointment (no Referral form required).** If a patient is referred to Oncology and you would like a clinical trial to be considered, please make a note on the referral form.

Clients may be responsible for the initial examination fee for the screening visit (currently $132). While additional tests may be required, each trial has different funding; therefore, an explanation of costs will be reviewed with the client.

**CLINICAL TRIALS COORDINATOR**

Gina Galyon, LVMT  
865-974-8387  |  FAX: 865-974-5213  |  ggalyon@utk.edu  